Drug intelligence / Profile preview

RQ-00350215

Development stage: Preclinical
Lead developer: Hisamitsu Pharmaceutical
Modality: Small Molecules
Administration: Transdermal

Overview

RQ-00350215 is a novel small molecule sodium channel blocker discovered by RaQualia Pharma and developed in collaboration with Hisamitsu Pharmaceutical for the treatment of chronic pain. The compound functions by blocking voltage-gated sodium channels, specifically targeting the Nav1.7 and Nav1.8 subtypes, which are essential for the transmission of nociceptive (pain) signals. By inhibiting these channels, the drug aims to reduce pain signaling in the peripheral nervous system. As of the current reporting, the program is in the discovery stage of research and development.

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on RQ-00350215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-00350215.

Explore the full profile